| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5648517 | Journal of the American Academy of Dermatology | 2017 | 19 Pages |
Abstract
In this head-to-head, double-blind study, secukinumab demonstrated sustained superior efficacy in comparison with ustekinumab in clearing skin through week 52, greater improvement in quality of life, and a favorable and comparable safety profile.
Keywords
PSAPASI 100PASI 90Psoriasis area and severity index (PASI)HAQ-DIsecukinumabEQ-5D-3LPASI 75ustekinumabDLQINRIHRQOLpsoriatic arthritisEfficacySafetyinterleukinPASIDermatology Life Quality Indexadverse eventMultiple imputationpsoriasis area and severity indexPsoriasisClinical trialHealth-related quality of life
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Andrew MD, MBA, Kristian MD, Tsen-Fang MD, Stephen MD, PhD, Francisco MD, Külli MD, PhD, Michael MD, BSc, Andreas MD, Ronald MD, FRCPC, Sophie MSc, Ruquan MSc, Marina MD, Diamant MD,